儿童患者胺碘酮与N-去乙基胺碘酮群体药代动力学研究
该研究在55例心律失常(主要为室上性心动过速)患儿中构建胺碘酮及其活性代谢物DEA的群体药代动力学模型,基于72个浓度点。模型显示胺碘酮清除率6.32 L/h、口服生物利用度0.362,终末半衰期34天,药代动力学变异大,提示治疗药物监测可能有助于优化个体疗效与安全性。
要点
- 胺碘酮在患儿中清除率6.32 L/h,终末半衰期长达34天。
- 口服生物利用度为0.362,DEA终末半衰期14.5天。
- 药代动力学个体间变异大,建议考虑治疗药物监测。
核心结论
- 胺碘酮在患儿中呈现高药代动力学变异,治疗药物监测可能有助于改善个体疗效与安全性。
研究设计与样本
- 在法国Necker-Enfants malades医院儿科重症监护和儿科心内科开展,纳入55例心律失常患儿,收集72个胺碘酮和DEA浓度点。
主要发现
- 胺碘酮消除清除率为6.32 L/h(RSE 31%),室间清除率为7.14 L/h(RSE 26%)。
- V1为167 L(RSE 31%),V2为3930 L(RSE 32%)。
- 口服生物利用度为0.362(RSE 21.5%)。
- 清除率个体间变异(ω)为0.462(RSE 21%)。
- 胺碘酮和DEA的终末半衰期分别为34天和14.5天。
关键数值与推荐
- 按体重异速缩放(归一化至70 kg)估算清除率与分布容积。
- 为3个体重区间、2个时间段建立了给药方案。
临床怎么用
- 临床可参考体重分层的给药方案,并关注高变异下个体化给药的必要性。
- 对疗效不佳或疑似毒性患儿,可考虑开展治疗药物监测。
局限性
- 样本量较小(55例患儿、72个浓度点),可能限制参数估计的精度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The population pharmacokinetics of amiodarone and its active metabolite, N-desethylamiodarone (DEA) were investigated in paediatric patients with arrhythmias, mainly supraventricular tachycardias. A total of 55 patients from the Department of Pediatric Intensive Care and Pediatric Cardiology at Necker-Enfants malades Hospital (Paris, France) provided 72 concentrations for both amiodarone and DEA following repeated oral or intravenous administration. Blood samples drawn for biological analyses were used for drug concentrations. Plasma amiodarone concentrations were measured by a liquid chromatography method coupled with mass spectrometry and the data were modelled using the software Monolix 2019R2. Parent pharmacokinetics was described with a 2-compartment open model and the metabolite formation was connected to the central parent compartment. Parameter estimates scaled allometrically on bodyweight (normalized to 70 kg) were, respectively (% relative standard errors, RSEs), 6.32 (31%) and 7.14 L/h (26%) for elimination (CL) and intercompartmental clearances and 167 (31%) and 3930 (32%) L for V1 and V2 . Oral bioavailability was 0.362 (21.5%). The clearance between subject variability (ω, square root of the variance) was 0.462 (RSE 21%). The proportional residual variabilities were respectively 0.453 (RSE 13%) and 0.423 (RSE 12%) for amiodarone and DEA respectively. The terminal half-lives were 34 and 14.5 days for amiodarone and DEA, respectively. A dosage schedule was established for 3 weight bands in 2 time periods. The high pharmacokinetic variability suggests that therapeutic drug monitoring might be useful to improve individual efficacy and safety.
引用
- Lehnert A, Foissac F, Bouazza N, et al. Amiodarone/N-desethylamiodarone population pharmacokinetics in paediatric patients. Br J Clin Pharmacol. 2022. PMID: 35816412. doi:10.1111/bcp.15458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。